Shomron Ben-Horin
@ShomronH
M.D.Professor & Chief#Gastroenterology Dept, Sheba Medical Center. Focus# Crohns&Colitis. Director#IBDPassport. Worked Israel, USA, China. Ìnnovate and help!
Now in press at @AGA_CGH promising results PCB trial of curcumin-QingDai (CurQD) botanical combo. Shown to be a unique AhR agonist which was effective for active UC pts, half of whom IMM/biologics exprienced. my COI of note. @AmerGastroAssn #nutrition cghjournal.org/article/S1542-…
Elegant study on isolated anastomotic ulceration ("pure"i2a) shows they also predict higher recurrence risk (and linked with dysbiosis). Bears to reason, as they are rarely seen in non-IBD anastomoses
1/ Our new study at IBD Journal linking Isolated Anastomotic Ulcer (IAU) to long-term recurrence post-operatively and microbiome shifts. @MichielBak @poliverasendra @TurpinWilliams @HaimLeiboIBD @guthealthmd @SinaiHealth @AnthonydeBuck @mantaj_brar academic.oup.com/ibdjournal/adv…
Very interesting study of Yao (NOD2 associated) syndrome, expanding the scope of IBD adjacent disorders (like CMUSE, but very different). Mostly GI motility manifestations but periodic fevers and joints are more like FMF/TRAP.
⭐️I am thrilled to share our latest publication, which describes the gastrointestinal manifestations of Yao Syndrome (NOD2-associated autoinflammatory disease)! link.springer.com/article/10.100… #MedTwitter #GITwitter #rheumatology #rheumtwitter #YaoSyndrome #YAOS
A bombshell metaanalysis just landed in @AGA_CGH : Advanced therpies work better in colonic #Crohn vs. Ileal dis 😱 aTNFs/aIL23-aIL12/23 were all more effective in the colon, aIntegrin same efficacy in both(?), and JAKi were ONLY EFFECTIVE IN COLON.... cghjournal.org/article/S1542-…
If you read this month's Editor's Essential Reading, "Capsule Endoscopy–Guided Proactive Treat-to-Target Versus Continued Standard Care in Patients With Quiescent Crohn’s Disease," check out the corresponding editorial by @IBD_FloMD et al. ➡️ ow.ly/ryA350Wpkxs
Very cool pictorial. To add: Both Risa and Miri have Fc LALA mutation to reduce effector ADCC/CDC potential. In contrast, Gus is wild type Ab (unmutated, hence binds CD64=FcRI), but still given/4w or/8w. Whether wild type will yield ⬆️AE or better efficacy remains to be seen.
🎯 Extending the Half-Life of mAbs: Why It Matters in IBD In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems. 🧬 Enter Fc engineering: By tweaking the Fc region of…
We're scratching the surface in exploiting #IUS potential as a dynamic test in GI. Intetedting observation from @elrets
A physiological/philosophical conundrum On IUS Many patients with IBS have fluid filled loops of small bowel and sometimes a somewhat prominent and hyperechoic submucosa What causes the ⬆️ echogenicity? @CathyLuMD @KrugCleveland @DrMikeDolinger @BowelUltrasound @novakkerri
IUS also for monitoring acute severe UC. Intriguingly, loss of stratification (IUS transmural feature) correlated best with CRP (the transmural biomarker ).
Our study on IUS in ASUC out in @ACG_CTG! @IBDCedarsSinai @iUSCAN @BowelUltrasound 📍IUS bridges discrepancy b/w sx's &🩸markers 📍IBUS-SAS & Milan-UC > IUS-UC for detecting severe endo🔥 📍⬇️BWS correlated more w/ CRP and UCEIS than BWT journals.lww.com/ctg/abstract/9…
‼️Anyone interested in organ fibrosis please join us for the Keystone Fibrosis Symposium 2026 ‘Cross Organ Pathology and Pathways to Clinical Development’ ‼️Introduction video can be found here url.avanan.click/v2/r01/___http…. Registration 👉🏻 keysym.us/KSFibrosis26 @Suzanne_Devkota
💯 Thank u for sharing ! Really moving to hear. Wish u best of health
I’m this patient and I’m still using curqd and I’m still in remission!!
Nice case report from @natekrugliak and @guthealthmd in Toronto, on use of #CurQD for a #Crohn patient who flared after having to stop IFX due to dilated cardiomyopathy @UofT My COI of note share.google/VCZMzZp6dJicyZ…
As noted in this paper, we dont give prep to SB capsule. Unwarranted, and turns a pt-friendly procedure into much less so
The Visibility and Performance of Small Bowel Video Capsule Endoscopy With and Without Pre‐Procedural Purge Preparation in the Same Patients - Margalit Yehuda - 2025 @SHEBA_ @JGHofficial - Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/jg…
Welcome to Dr Nir Salomon as our guest at the @SickKidsNews 2025 Division of Gastroenterology, Hepatology and Nutrition Research Day. Nir is speaking about the development of CurQD as an example of new neutraceuticals as a treatment option for IBD.
Interesting angle on AhR avtivation by indole derivatives for maintaining barrier integrity and ameliorating IBD
IPA was reduced in #CD and #UC microbiomes (only n = 5), which is supported by larger studies, and is consistent with #antibiotic-induced suppression of IPA production. gut.bmj.com/content/72/8/1… sciencedirect.com/science/articl… microbiomejournal.biomedcentral.com/articles/10.11…
Seminal work by @Siew_C_Ng & @gilkaplan on global IBD evolution over a century. Intriguingly echoing similar patterns in #asthma Should we start calling IBD 'Allergic-immune disease' ? Or are we satisfied with 'Toxicogenic barrier disruption' ? Either way, environment rules
Over a decade since I collaborated with world-class epidemiologist @gilkaplan and his team, here is our long awaited paper out in @Nature reporting for the first time evolution of #ibd across 4 stages @HelmsleyTrust @IOIBD1 @CUHKMedicine @IBD_GIVES21 nature.com/articles/s4158…
Noting my COI, it' s personally really moving for me to recieve such heartwarming messages from pts in Spain treated with #CurQD. Grateful to our partner-friends there @naturcyte who facilitated this.
Jorge, paciente con colitis ulcerosa, llevaba más de 2 años en brote. Hoy vuelve a disfrutar de la vida gracias a CurQD. 🌿🩺 ¡Gracias por compartir tu historia! Si también eres paciente de EII, completa nuestro formulario clínico y recibe asesoramiento personalizado: 👉…
Clever pragmatic T2T trial. Looking forward to results.
Read the paper by Singh et al on "Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT)..." via bit.ly/44m1xrZ @davidhudesmanMD @Dana_Lukin @ibdtweets @vipuljairath #IBD
Still limited number, but reassuring important data on safety of Rota vaccine in bio-exposed newborns
Live rotavirus vaccination was provided after immune profile and assessment to infants born to mothers with IBD on biologics and appears to be safe despite infant detectable mAb concentration: ow.ly/mJva50VA7Cs @SeowCynthia @RPanaccione @kennethernest
A sub-study of CURE-CD trial: No benefit (=no need) of bowel preparation for SB #capsule-endocopy in CD pts, when each pt compared to him/herself (with/without prep). Supports similar studies comparing different pt groups. @SHEBA_ pubmed.ncbi.nlm.nih.gov/40176636
Small bowel inflammation proximal to ileocolonoscopy reach is important factor for prediction of long-term outcome in #Crohn ! Can be determined by DBE as in this nice study from 🇯🇵, or by #capsule-endoscopy
A substantial proportion of patients with CD exhibited ulcerations in the proximal ileum, which correlated with a poorer prognosis. These lesions proved challenging to heal, regardless of the type of biologic used. authors.elsevier.com/c/1ktXG_Z4R9HU…
Just saw pt with isolated persistent (7y) complex perianal fistula without any luminal CD, similar to nice series by @DrSamirAShah1 and @HannahWFiske in @IBDJournals A unique CD subset or a complicated cryptoglandular? To aTNF or not ? Still no answer pubmed.ncbi.nlm.nih.gov/39679162/
